{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T19:53:57Z","timestamp":1717444437337},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,11,25]],"date-time":"2009-11-25T00:00:00Z","timestamp":1259107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,11,25]],"date-time":"2009-11-25T00:00:00Z","timestamp":1259107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s10637-009-9348-z","type":"journal-article","created":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T09:08:17Z","timestamp":1259053697000},"page":"352-359","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618"],"prefix":"10.1007","volume":"29","author":[{"given":"Susanne M.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen K.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James N.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai-Hong I.","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan G.","family":"Urba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,11,25]]},"reference":[{"key":"9348_CR1","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMra0707975","volume":"359","author":"RI Haddad","year":"2008","unstructured":"Haddad RI, Shin DM (2008) Recent advances in head and neck cancer. N Engl J Med 359:1143\u20131154","journal-title":"N Engl J Med"},{"key":"9348_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.clon.2005.02.014","volume":"17","author":"X Le\u00f3n","year":"2005","unstructured":"Le\u00f3n X, Hitt R, Constenla M, Rocca A, Stupp R, Kov\u00e1cs AF, Amellal N, Bessa EH, Bourhis J (2005) A retrospective analysis of the outcome of patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol 17:418\u2013424","journal-title":"Clin Oncol"},{"key":"9348_CR3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171\u20132177","journal-title":"J Clin Oncol"},{"key":"9348_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1351\/pac198658050701","volume":"58","author":"Y Hirata","year":"1986","unstructured":"Hirata Y, Uemura D (1986) Halichondrins: antitumor polyether macrolides from a marine sponge. Pure Appl Chem 58:701\u2013710","journal-title":"Pure Appl Chem"},{"key":"9348_CR5","doi-asserted-by":"crossref","first-page":"15882","DOI":"10.1016\/S0021-9258(18)98491-7","volume":"266","author":"R Bai","year":"1991","unstructured":"Bai R, Paull K, Herald C, Malspeis L, Pettit G, Hamel E (1991) Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 266:15882\u201315889","journal-title":"J Biol Chem"},{"key":"9348_CR6","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1124\/mol.106.026641","volume":"70","author":"DA Dabydeen","year":"2006","unstructured":"Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJH, Pettit GR, Blunt JW, Munro MHG, Gussio R, Hamel E (2006) Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 70:1866\u20131875","journal-title":"Mol Pharmacol"},{"key":"9348_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086\u20131095","journal-title":"Mol Cancer Ther"},{"key":"9348_CR8","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","volume":"7","author":"T Okouneva","year":"2008","unstructured":"Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7:2003\u20132011","journal-title":"Mol Cancer Ther"},{"key":"9348_CR9","first-page":"1013","volume":"61","author":"MJ Towle","year":"2001","unstructured":"Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, Habgood GJ, Singer LA, DiPietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013\u20131021","journal-title":"Cancer Res"},{"key":"9348_CR10","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/jco.2005.23.16_suppl.3036","volume":"23","author":"TW Synold","year":"2005","unstructured":"Synold TW, Morgan RJ, Newman EM, Lenz HJ, Gandara DR, Colevas AD, Lewis MD, Doroshow JH (2005) A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California cancer consortium trial. J Clin Oncol 23:3036 Meeting Abstracts","journal-title":"J Clin Oncol"},{"key":"9348_CR11","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/jco.2007.25.18_suppl.1034","volume":"25","author":"JL Blum","year":"2007","unstructured":"Blum JL, Pruitt B, Fabian CJ, Rivera RR, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Fields SZ, Vahdat L (2007) Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer. J Clin Oncol 25:1034 Meeting Abstracts","journal-title":"J Clin Oncol"},{"key":"9348_CR12","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/jco.2005.23.16_suppl.3090","volume":"23","author":"KK Desai","year":"2005","unstructured":"Desai KK, Goel S, Mita A, Silberman S, Sicam J, Woeppel S, Macapinlac M, Berg K, Rowinski E, Mani S (2005) Dose escalation and pharmacokinetic (pk) study of E 7389, a microtubule-binding drug in patients (pts) with advanced solid tumors. J Clin Oncol 23:3090 Meeting Abstracts","journal-title":"J Clin Oncol"},{"key":"9348_CR13","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1200\/JCO.2005.03.0981","volume":"23","author":"EH Rubin","year":"2005","unstructured":"Rubin EH, Rosen L, Rajeev V, Wiggins L, Sicam J, Silberman S, Shapiro G (2005) Phase I study of E7389 administered by 1\u00a0hour infusion every 21\u00a0days. J Clin Oncol 23:2054 Meeting Abstracts","journal-title":"J Clin Oncol"},{"key":"9348_CR14","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/jco.2005.23.16_suppl.2013","volume":"23","author":"N Wong","year":"2005","unstructured":"Wong N, Desjardins C, Silberman S, Lewis M (2005) Pharmacokinetics (PK) of E7389, a Halichondrin B analog with novel anti-tubulin activity: results of two phase I studies with different schedules of administration. J Clin Oncol 23:2013 Meeting Abstracts","journal-title":"J Clin Oncol"},{"key":"9348_CR15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1200\/jco.2006.24.18_suppl.653","volume":"24","author":"JB Forero","year":"2006","unstructured":"Forero JB, Heiskala MK, Meneses N, Chandrawansa K, Fang F, Shapiro G, Fields SZ, Silberman S, Vahdat L (2006) E7389, a novel anti-tubulin, in patients with refractory breast cancer. J Clin Oncol 24:653 Meeting Abstracts","journal-title":"J Clin Oncol"},{"key":"9348_CR16","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","volume":"27","author":"LT Vahdat","year":"2009","unstructured":"Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, DaCosta NA, Chuang E, Smith J, O\u2019Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27:2954\u20132961","journal-title":"J Clin Oncol"},{"key":"9348_CR17","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1200\/jco.2006.24.18_suppl.7106","volume":"24","author":"A Das","year":"2006","unstructured":"Das A, Spira A, Iannotti N, Savin M, Zang E, Datta K, Shapiro G, Patturajan M, Silberman S (2006) A phase II study of a novel anti-tubulin, E7389, in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 24:7106 Meeting Abstracts","journal-title":"J Clin Oncol"},{"key":"9348_CR18","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/jco.2007.25.18_suppl.7546","volume":"25","author":"AI Spira","year":"2007","unstructured":"Spira AI, Iannotti NO, Savin MA, Neubauer M, Gabrail NY, Yanagihara R, Datta KK, Zang EA, Fields SZ, Das A (2007) Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25:7546 Meeting Abstracts","journal-title":"J Clin Oncol"},{"key":"9348_CR19","unstructured":"de Bono J, Maroto P, Calvo E, Sonpavde G, Cartwright TH, Loesch D, Feit K, Zang EA, Wanders J, Petrylak DP (2009) Phase II study of eribulin mesylate (E7389) in patietns (pts) with metastatic castraction-resistant prostate cancer (CRPC) stratified by prior taxane therapy"},{"key":"9348_CR20","doi-asserted-by":"crossref","first-page":"15513","DOI":"10.1200\/jco.2007.25.18_suppl.15513","volume":"25","author":"R Molife","year":"2007","unstructured":"Molife R, Cartwright TH, Loesch DM, Garbo LE, Sonpavde G, Calvo E, Das A, Wanders J, Petrylak DP, de Bono J (2007) Phase II multicenter, two-stage study of E7389 in patients with hormone refractory prostate cancer with advanced and\/or metastatic disease stratified by prior chemotherapy. J Clin Oncol 25:15513 Meeting Abstracts","journal-title":"J Clin Oncol"},{"key":"9348_CR21","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H-R, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116\u20131127","journal-title":"N Engl J Med"},{"key":"9348_CR22","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1002\/cncr.23442","volume":"112","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J (2008) Overview of the efficacy of cetuximab in recurrent and\/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112:2710\u20132719","journal-title":"Cancer"},{"key":"9348_CR23","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2005.01.057","volume":"23","author":"MK Gibson","year":"2005","unstructured":"Gibson MK, Li Y, Murphy B, Hussain MHA, DeConti RC, Ensley J, Forastiere AA (2005) Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the eastern cooperative oncology group. J Clin Oncol 23:3562\u20133567","journal-title":"J Clin Oncol"},{"key":"9348_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9348_CR25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1200\/jco.2008.26.15_suppl.1084","volume":"26","author":"LT Vahdat","year":"2008","unstructured":"Vahdat LT, Twelves C, Allison MK, Cortes JA, Campone M, Shuster DE, Wanders J, Fang F, Gurnani RD, Blum JL (2008) Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy. J Clin Oncol 26:1084 Meeting Abstracts","journal-title":"J Clin Oncol"},{"key":"9348_CR26","first-page":"409","volume":"45","author":"PM Specenier","year":"2009","unstructured":"Specenier PM, Vermorken JB (2009) Current concepts for the management of head and neck cancer: Chemotherapy. Oral Oncology, Corrected Proof 45:409\u2013415","journal-title":"Corrected Proof"},{"key":"9348_CR27","doi-asserted-by":"crossref","unstructured":"Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, Williamson SK, Atkins JN, Schuller DE, Ensley JF: Evaluation of the combination of docetaxel\/carboplatin in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Investigation. Taylor & Francis Ltd, pp 182\u2013188","DOI":"10.1080\/07357900701209061"},{"key":"9348_CR28","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1200\/JCO.20.6.1593","volume":"20","author":"BS Glisson","year":"2002","unstructured":"Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA (2002) Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 20:1593\u20131599","journal-title":"J Clin Oncol"},{"key":"9348_CR29","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","volume":"10","author":"A Forastiere","year":"1992","unstructured":"Forastiere A, Metch B, Schuller D, Ensley J, Hutchins L, Triozzi P, Kish J, McClure S, VonFeldt E, Williamson S (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10:1245\u20131251","journal-title":"J Clin Oncol"},{"key":"9348_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/annonc\/mdf103","volume":"13","author":"G Numico","year":"2002","unstructured":"Numico G, Merlano M (2002) Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer. Ann Oncol 13:331\u2013333","journal-title":"Ann Oncol"},{"key":"9348_CR31","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.1200\/JCO.2005.07.120","volume":"23","author":"RS Herbst","year":"2005","unstructured":"Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23:5578\u20135587","journal-title":"J Clin Oncol"},{"key":"9348_CR32","doi-asserted-by":"publisher","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","volume":"23","author":"B Burtness","year":"2005","unstructured":"Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an eastern cooperative oncology group study. J Clin Oncol 23:8646\u20138654","journal-title":"J Clin Oncol"},{"key":"9348_CR33","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1200\/JCO.2006.07.6547","volume":"25","author":"LL Siu","year":"2007","unstructured":"Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang W, Dancey J, Eisenhauer EA, Winquist E (2007) Phase I\/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a princess Margaret Hospital Phase II consortium and National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 25:2178\u20132183","journal-title":"J Clin Oncol"},{"key":"9348_CR34","first-page":"247","volume":"10","author":"EEW Cohen","year":"2009","unstructured":"Cohen EEW, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan D-H, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE (2009) Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I\/II study. The Lancet Oncology, Corrected Proof 10:247\u2013257","journal-title":"Corrected Proof"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9348-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-009-9348-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9348-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9348-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:48:58Z","timestamp":1678510138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-009-9348-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,25]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["9348"],"URL":"https:\/\/doi.org\/10.1007\/s10637-009-9348-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,25]]},"assertion":[{"value":"22 September 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}